Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of the Interest of Radiotherapy After 4 or 6 Cycles of CHOP 14 Rituximab Regimen of Chemotherapy , Patients With Agressive Localized Lymphoma

NCT00841945 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT00841945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00841945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of the Interest of Radiotherapy After 4 or 6 Cycles of CHOP 14 Rituximab Regimen of Chemotherapy , Patients With Agressive Localized Lymphoma
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2005
Completion date
February 28, 2017
Enrollment
334 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma